Physician profile
Gem Martin
NPI 1689135329
$710.28
in general payments reported to CMS, 2019-2025
16 companies · $98.76 in 2025
The $98.76 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $173 · 2022: $150 · 2023: $87.71 · 2024: $201 · 2025: $98.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $387.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.99 | 2022 | |
| Esperion Therapeutics, INC. | $110.86 | 2021 | |
| Pfizer INC. | $86.10 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $63.42 | 2025 | Breztri, Airsupra |
| Pharmacyclics LLC, An Abbvie Company | $57.53 | 2021-2022 | |
| Novo Nordisk INC | $44.70 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $38.20 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $36.28 | 2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $26.89 | 2024 | |
| Abbott Laboratories | $22.84 | 2024 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.74 | 2025 | Caplyta |
| Paratek Pharmaceuticals, INC. | $18.50 | 2023 | Nuzyra |
| Corcept Therapeutics | $18.39 | 2021 | |
| Amgen INC. | $15.85 | 2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $13.60 | 2024 | Trelegy Ellipta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gem Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.